EGFR+ Lung Cancer

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

In a&nbsp;Targeted Oncology case-based peer perspectives live discussion, Heather A. Wakelee, MD, discussed treatment with tyrosine kinase inhibitor treatment options for a real-world Hispanic patient with EGFR-mutant non&ndash;small cell lung cancer.<br /> &nbsp;

A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC

A 63-Year-Old Woman With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

In an interview with&nbsp;Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br /> &nbsp;

Lung Cancer

In response to&nbsp;frequent and substantial changes in the treatment of non&ndash;small cell lung cancer in the frontline set&shy;ting, the American Society of Clinical Oncology has partially updated its 2017 guide&shy;line for the treatment of patients with stage IV disease without driver mutations.

Patients harboring IDH1/2 muta&shy;tions may receive benefit by the use of PARP inhibitors, with investigators initi&shy;ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

Julie R. Brahmer, MD, discusses the circumstances in which a physician can choose osimertinib over other EGFR tyrosine kinase inhibitors for patients with&nbsp;<em>EGFR</em>-mutant lung cancer.

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the&nbsp;Journal for ImmunoTherapy of Cancer.